
    
      Studies have shown the feasibility of detecting mutation status by blood circulating tumor
      DNA (ctDNA) in lung cancer patients.

      The investigators plan to test the blood ctDNA in surveillance of surgical lung cancer
      patients. And evaluate the correlation between ctDNA level with tumor relapse or metastasis.
    
  